Evidence map›Paper›PMID 38898728›Full record

ArticleAdvanced healthcare materials2025

Polymerized Salicylic Acid Microparticles Reduce the Progression and Formation of Human Neutrophil Extracellular Traps (NET)s.

Emma R Brannon, Logan D Piegols, Gillian Cady, Daniel Kupor, Xueqi Chu, M Valentina Guevara, Mariana R N Lima, Yogendra Kanthi, David J Pinsky, Kathryn E Uhrich and 1 more

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Emma R BrannonDepartment of Chemical Engineering, University of Michigan, 2800 Plymouth Road, NCRC B28, Ann Arbor, MI, 48109, USA.
Logan D PiegolsDepartment of Chemical Engineering, University of Michigan, 2800 Plymouth Road, NCRC B28, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-4919-3312
Gillian CadyDivision of Cardiovascular Medicine, Samuel and Jean Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0003-2035-5178
Daniel KuporDepartment of Chemical Engineering, University of Michigan, 2800 Plymouth Road, NCRC B28, Ann Arbor, MI, 48109, USA.ORCID 0000-0001-9331-1454
Xueqi ChuDepartment of Chemical Engineering, University of Michigan, 2800 Plymouth Road, NCRC B28, Ann Arbor, MI, 48109, USA.
M Valentina GuevaraDepartment of Chemical Engineering, University of Michigan, 2800 Plymouth Road, NCRC B28, Ann Arbor, MI, 48109, USA.
Mariana R N LimaDepartment of Chemistry, University of California Riverside, Riverside, CA, 92521, USA.
Yogendra KanthiDivision of Cardiovascular Medicine, Samuel and Jean Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-5660-5194
David J PinskyDivision of Cardiovascular Medicine, Samuel and Jean Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-7640-6694
Kathryn E UhrichDepartment of Chemistry, University of California Riverside, Riverside, CA, 92521, USA.ORCID 0000-0001-7273-7528
Omolola Eniola-AdefesoDepartment of Chemical Engineering, University of Michigan, 2800 Plymouth Road, NCRC B28, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-8728-6608

Funding

TRAINING IN MOLECULAR AND CELLULAR CARDIOLOGYT32HL007853 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David J. Pinsky · 1996 to 2026
$11.6M
Purinergic regulation of Innate Immunity to promote Venous HomeostasisR01HL150392 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PINSKY, DAVID J. · 2020 to 2024
$2.2M
Development of PolyAspirin Particles for Therapeutic Intervention in ALI/ARDS via the Passive Restraint of Neutrophil FunctionR01HL145709 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SINGER, BENJAMIN HERSCHEL · 2020 to 2023
$1.6M
Dr. Ralph and Marian Falk Medical Research TrustNational Science Foundation Graduate Research Fellowship ProgramNHLBI NIH HHS R01 HL145709NHLBI NIH HHS R01HL145709NHLBI NIH HHS R01 HL150392NHLBI NIH HHS R01HL150392NHLBI NIH HHS T32 HL007853NHLBI NIH HHS T32HL007853
6 · The paper itself

Abstract

Neutrophils can contribute to inflammatory disease propagation via innate mechanisms intended for inflammation resolution. For example, neutrophil extracellular traps (NETs) are necessary for trapping pathogens but can contribute to clot formation and blood flow restriction, that is, ischemia. Currently, no therapeutics in the clinic directly target NETs despite the known involvement of NETs contributing to mortality and increased disease severity. Vascular-deployed particle-based therapeutics are a novel and robust alternative to traditional small-molecule drugs by enhancing drug delivery to cells of interest. This work designs a high-throughput assay to investigate the immunomodulatory behavior and functionality of salicylic acid-based polymer-based particle therapeutics against NETosis in human neutrophils. Briefly, this work finds that polymeric composition plays a role, and particle size can also influence rates of NETosis. Salicylate-based polymeric (Poly-SA) particles are found to functionally inhibit NETosis depending on the particle size and concentration exposed to neutrophils. This work demonstrates the high throughput method can help fast-track particle-based therapeutic optimization and design, more efficiently preparing this innovative therapeutics for the clinic.

Indexed as

Extracellular TrapsNeutrophilsSalicylic AcidHumansParticle SizePolymerizationPolymersPolymersSalicylic Acidinflammationneutrophil extracellular trapsparticle‐based therapeutics

Identifiers

PMID38898728
PMCPMC11628640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.